The camptothecins Journal Article
| Authors: | Pizzolato, J.; Saltz, L. B. |
| Article Title: | The camptothecins |
| Abstract: | Supported by detailed understanding of their mechanism of action, and facilitated by chemical manipulations that have amplified their solubility, the camptothecins have advanced to the forefront of several areas of therapeutic and developmental chemotherapy. Additive and synergistic laboratory interactions with other cytotoxic drugs have been exploited to allow development of camptothecin-based multidrug regimens, which are showing important activity in several malignancies. Topotecan and irinotecan are already in widespread use in clinical practice, and newer agents with promising preclinical activity are in various stages of clinical assessment. As knowledge of molecular and biochemical mechanisms of action and resistance continues to expand, newer and better camptothecin-based strategies for treatment of malignant disease are likely to evolve. |
| Keywords: | cancer chemotherapy; cancer survival; protein expression; clinical trial; drug activity; neutropenia; review; cisplatin; fluorouracil; diarrhea; drug efficacy; drug potentiation; drug safety; nonhuman; liver dysfunction; drug targeting; paclitaxel; topotecan; antineoplastic agent; dna replication; clinical practice; colorectal cancer; ovarian neoplasms; animals; carboplatin; bolus injection; apoptosis; ovary cancer; peritoneum cancer; bone marrow; bone marrow suppression; etoposide; blood toxicity; lung non small cell cancer; carcinoma, non-small-cell lung; lung neoplasms; 7 ethyl 10 hydroxycamptothecin; antineoplastic agents, phytogenic; camptothecin; cancer cell culture; caspase; structure-activity relationship; dna strand breakage; irinotecan; digestive system cancer; flushing; gastrointestinal neoplasms; molecular mechanics; lung small cell cancer; clinical study; drug mechanism; cyclooxygenase 2 inhibitor; folinic acid; drug clearance; malignant neoplastic disease; loperamide; drug metabolism; drug half life; dna helix; drug metabolite; dna topoisomerase (atp hydrolysing); drug contraindication; drug sensitivity; exatecan; hemorrhagic cystitis; science; drug use; granulocytopenia; atropine; dna cleavage; dna topoisomerase; dna topoisomerases, type i; muscle cramp; carboxylic acid; chemical modification; carcinoma, small cell; drug solubility; 9 aminocamptothecin; neomycin; sweating; lactone; gastrointestinal carcinoma; colony stimulating factor; rubitecan; gilbert disease; humans; human; female; priority journal; acetorphan; afeletecan; camptotheca; drug glucuronidation |
| Journal Title: | Lancet |
| Volume: | 361 |
| Issue: | 9376 |
| ISSN: | 0140-6736 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2003-06-28 |
| Start Page: | 2235 |
| End Page: | 2242 |
| Language: | English |
| DOI: | 10.1016/s0140-6736(03)13780-4 |
| PUBMED: | 12842380 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 25 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work